Oral cancer overexpressed 1 (ORAOV1) regulates cell cycle and apoptosis in cervical cancer HeLa cells by Jiang, Lu et al.
RESEARCH Open Access
Oral cancer overexpressed 1 (ORAOV1) regulates
cell cycle and apoptosis in cervical cancer HeLa
cells
Lu Jiang
1, Xin Zeng
1, Zhi Wang
1, Ning Ji
2, Yu Zhou
1, Xianting Liu
2, Qianming Chen
1*
Abstract
Background: Oral Cancer Overexpressed 1 (ORAOV1) is a candidate protooncogene locating on 11q13. Recent
studies show that ORAOV1 acts as a primary driving force behind 11q13 gene amplification and plays a functional
role in the tumorigenesis in a variety of human squamous cell carcinomas (SCCs). According to the results of
molecular cytogenetic methods, 11q13 was characterized to be a high-level and recurrent amplification
chromosomal site in cervical cancers. Up till now, the role of ORAOV1 in cervical cancer is unknown. The purpose
of this study is to elucidate the function of ORAOV1 in cervical cancer cell growth by studying its roles in HeLa
cells using small interfering RNA.
Results: Functional analyses revealed that ORAOV1 was involved in the regulation of HeLa cell growth through its
effect on cell cycle and apoptosis. Silence of ORAOV1 in HeLa cells downregulated the expression of Cyclin A,
Cyclin B1 and Cdc2, and led to a distinct S cell cycle arrest. Moreover, knockdown of ORAOV1 expression activated
both extrinsic and intrinsic apoptotic pathways and led to apoptosis in HeLa cells through its effect on the
expression of several apoptosis related proteins such as P53, Bcl-2, Caspase-3, Caspase-8, Caspase-9 and
cytochrome c. Interestingly, the expression of Cyclin D1, a pivotal gene for cervical cancer tumorigenesis, was also
found to be reduced in ORAOV1 silenced HeLa cells.
Conclusion: Our findings indicate that ORAOV1 has an important role in regulating cell growth of cervical cancer
HeLa cells through regulating the cell cycle and apoptosis. Thus, it may be a crucial protooncogene and a novel
candidate therapeutic target for cervical cancer.
Background
Oral Cancer Overexpressed 1 (ORAOV1) is a candidate
protooncogene in a variety of human squamous cell car-
cinomas (SCCs) [1]. According to previous studies,
ORAOV1 was first identified by Huang and his collea-
gues at chromosomal band 11q13 [1]. It was supposed
to be a primary driving force behind 11q13 gene ampli-
fication and regarded as a candidate oncogene with a
role in the development and progression of various
human SCCs [1]. In following years, several clinical stu-
dies showed that the expression level of ORAOV1 was
tightly correlated with prognosis-related clinicopatholo-
gical parameters and clinical grades in several SCCs
such as esophageal squamous cell carcinoma and oral
squamous cell carcinoma (OSCC) [2,3]. Further func-
tional studies showed that ORAOV1 may have an
important role in the tumorigenesis of OSCC by taking
part in the regulation of cell growth and tumor angio-
genesis [4]. Therefore, it is suggested that ORAOV1
may be a valuable biological marker in SCCs.
Chromosomal band 11q13 has been proved to be one
of the most frequently amplified regions in a variety of
SCCs [1], and its rearrangements are regarded to be
independent prognostic factors for several SCCs [5-7].
Because of its tight correlation with SCCs, chromosomal
band 11q13 is suggested to be one of the most frequent
tumor related chromosome regions in SCCs. In cervical
cancers, using a combination of molecular cytogenetic
methods, 11q13 was also characterized as a high-level
and recurrent amplification chromosomal site [8].
Because of significant correlation between 11q13 and
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11q13 amplification, it is of great interest to determine
whether ORAOV1 is also involved in the tumorigenesis
of cervical cancer or if it is a candidate protooncogene
or a potential therapeutic target in cervical cancers as it
is in other kinds of SCCs.
HeLa cells are one of the most representative cervix
squamous carcinoma cell lines. Based on the results of
comparative genomic hybridization (CGH), HeLa cells
have an amplification of 11q13 [9]. We chose HeLa cells
to investigate the biological functions of ORAOV1 in
cervical cancer tumorigenesis through a loss-of-function
study by small interfering RNA (siRNA) [10,11]. In this
study, we reported for the first time that silence of
ORAOV1 in HeLa cells significantly inhibited cell
growth through inducing S-phase cell cycle arrest and
apoptosis. Thus, we deduce that ORAOV1 plays a cru-
cial role in cervical cancer tumorigenesis, and may be a
novel protooncogene and candidate therapeutic target
for cervical cancer.
Results
ORAOV1 silencing inhibits cell growth and colony
formation ability of HeLa cells in vitro
To study the functions of ORAOV1 in HeLa cell
growth, we knocked down ORAOV1 in HeLa cells by
ORAOV1 siRNA as described in the Materials and
Methods section. Our results showed that ORAOV1 was
successfully silenced by ORAOV1 siRNA at both the
mRNA level and the protein level (Figure 1A). Upon
transfection, an apparent suppression of cell growth was
observed in ORAOV1 silenced HeLa cells (Figure 1B).
At 96 hours after transfection, the viability of the
ORAOV1 siRNA transfected HeLa cells decreased by
about 80% compared with the controls according to the
MTT assay (p < 0.001) (Figure 1C). Since colony forma-
tion ability is regarded as an important characteristic of
tumor growth in vitro, we examined the effect of
ORAOV1 silencing on HeLa cell colony formation abil-
ity. According to plate colony assay, the colony forma-
tion ability were obviously suppressed in the ORAOV1
silenced HeLa cells, and its relative colony formation
efficiency decreased to 5-10% of that of the control ones
(p < 0.001) (Figure 1D).
ORAOV1 silencing induces S-phase cell cycle arrest in
HeLa cells
To study the potential mechanisms by which ORAOV1
silencing inhibit HeLa cell growth, the effect of
ORAOV1 siRNA on cell cycle was evaluated by flow
cytometry assay. As shown in Figure 2A, at 48 hours
after treatment, the percentages of S-phase cells in
blank and negative siRNA-transfected HeLa cells were
around 40-50%, whereas that in the ORAOV1 siRNA-
transfected HeLa cells were about 60%. In the
meantime, 10-15% of blank and negative siRNA-trans-
fected HeLa cells were in G2-phase, compared with
about 5% in the ORAOV1 siRNA-transfected group.
However, no obvious alternation was found in the per-
centage of G1-phase cells in ORAOV1 siRNA-trans-
fected HeLa cells compared with the control. Therefore,
ORAOV1 silencing may arrest the cell cycle at the S-
phase by inhibiting the S to G2 transition in HeLa cells.
Next, we performed BrdU incorporation assay and
Western blot assay to investigate the effect of ORAOV1
silencing on DNA synthesis and cell cycle regulators.
Our results showed that ORAOV1 silence in HeLa cells
caused suppression of DNA synthesis (Figure 2B). In the
meantime, a down regulated expression level of Cyclin
A, Cyclin B1, Cyclin D1 and Cdc2 was also detected
(Figure 2C). These results indicated that ORAOV1 silen-
cing may regulate the cell cycle in HeLa cells by regulat-
ing DNA synthesis and the expression of several cell
cycle regulators.
ORAOV1 silencing induces apoptosis in HeLa cells
To study whether the ORAOV1 silencing induced HeLa
cell growth inhibition was related to cell apoptosis, the
effect of ORAOV1 siRNA on cell apoptosis was evalu-
ated by flow cytometry using PI staining and Annexin-V
& PI double staining. As shown in Figure 3A, the per-
centage of cells in the pre-G1 (apoptotic) fraction in
blank, negative siRNA-transfected, and ORAOV1
siRNA-transfected HeLa cells were 2.9%, 3.4%, and
34.3%, respectively. Similar results had been got by
Annexin-V & PI double staining. As seen in Figure 3B,
the apoptosis rate (Annexin-V +/PI - and Annexin-V
+/PI +) of the blank, negative siRNA-transfected, and
ORAOV1 siRNA-transfected HeLa cells were about 5%,
5%, and 30%, respectively. Together, these data sug-
gested that ORAOV1 silencing might inhibit the growth
of HeLa cells through initiating cell apoptosis.
It is known that apoptosis could be initiated through
two signal pathways; the extrinsic and intrinsic pathways
[12,13]. We sought to determine which pathway did
ORAOV1 silencing lead to activate by examining the
important regulators in these two signal pathways. As
shown in Figure 3C, the protein level of P53 was up-
regulated by ORAOV1 silencing, while Bcl-2 was mark-
edly down-regulated. In the meantime, the protein level
of cytochrome c in mitochondria were detected to
decrease accompanied by its increase in the cytoplasm.
In addition, Caspase 8, 9 and 3 were all found to be
activated upon ORAOV1 silence. These data suggested
that ORAOV1 silencing could activate cell apoptosis in
HeLa cells through extrinsic and intrinsic pathways.
ORAOV1 silencing suppresses the growth of HeLa cell
xenografts in vivo
To test whether the ORAOV1 silencing can affect the
growth of HeLa cells in vivo, the tumor formation assay
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As shown in Figure 4A, the growth rate of xenografts in
ORAOV1 siRNA group was slower than that of the con-
trol groups, especially in the first 20 days. The reduction
of average tumor volume in the ORAOV1 siRNA group
reached about 60-70% compared with the control
groups. Moreover, at the end of the experiment, the
average tumor weight of the excised tumors from
ORAOV1 siRNA group decreased to about 40% of the
control groups (Figure 4B). Furthermore, according to
the results of HE staining (Figure 4C), necrosis occurred
in most of the ORAOV1 siRNA group xenografts in the
process of tumor formation.
Discussion
Cervical cancer is the second most deadly gynecologic
malignancy in the world [14,15]. Although it is now
regarded as a potentially preventable disease, there is
high risk of recurrence and the poor survival rate make
a compelling need to explore novel therapeutic targets
for its management [16]. It is now well known that the
progression of all cancers is characterized by increased-
cell proliferation and decreased-apoptosis. Thus,
searching for molecular regulators of tumor cell growth
has been an important goal of cancer studies. In this
study, we present novel evidence that ORAOV1 plays an
important role in the regulation of cell growth in cervi-
cal cancer HeLa cells. ORAOV1 silence in HeLa cells
induces S phase cell cycle arrest by suppression DNA
synthesis and regulating the expression of several cell
cycle regulators, such as Cyclin A, Cyclin B1 and Cdc2.
Moreover, it triggers cell apoptosis in HeLa cells by acti-
vating both intrinsic and extrinsic pathways. Interest-
ingly, ORAOV1 is also found to regulate the growth of
HeLa cells probably through its effect on Cyclin D1,
which is a pivotal regulator in the tumorigenesis of cer-
vical cancer [17,18]. Since all these findings are observed
in 11q13 amplified HeLa cells, further studies in other
cervical cancer cell lines are still needed to demonstrate
the vital functions of ORAOV1 in cervical cancers.
Cell cycle progression is strictly regulated by a series
of Cyclins and Cyclin-dependent kinases (CDKs). The
Cyclin-CDK complexes act as checkpoints at certain cell
cycle phase transition. In eukaryotic cells, checkpoints
secure the fidelity of chromosome transmission. When
DNA damage or incomplete DNA replication happens,
Figure 1 ORAOV1 silencing inhibits cell growth and colony formation ability in HeLa cells. (A) The expression levels of ORAOV1 mRNA
and ORAOV1 protein in HeLa cells upon transfection with 100 nM ORAOV1 siRNA for 48 hrs were analyzed by real time PCR and Western blot
assay respectively. 100 nM non-targeting siRNA-transfected HeLa cells and blank cells were used as controls. Results represent the means ± SE (n
= 3). *, P < 0.05. (B) The effect of ORAOV1 silencing on HeLa cell growth. (C) Examination the effect of ORAOV1 silencing on HeLa cell
proliferation by MTT assay. Results represent the means ± SE (n = 3). *, P < 0.001. (D) Test the effect of ORAOV1 silencing on HeLa cell colony
formation ability by plate colony assay. The relative colony formation efficiency of the blank cells was set as 1. Each column represents a mean
value of triplicate experiments in each group. Data are Mean ± SE, *, P < 0.001.
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to previous studies, Cyclin A, Cyclin E, Cdc2 and Cdk2
are important regulators in the cell cycle transition from
St oG 2 phase [19-21]. Moreover, in association with
Cdk2, Cyclin A and E are the major regulators of the
activity of Cdc 25B and Cdc 25C, which play important
roles in the S phase and G2/M phase [22]. For S-to-G2
transition, both complexes of Cdc2-Cyclin A and Cdc2-
Cyclin B1 act as vital regulators [20,23]. In our study,
DNA synthesis was found to be inhibited upon
ORAOV1 silence. In the meantime, S phase cell cycle
arrest was also detected. Therefore, it may be deduced
that ORAOV1 silence in HeLa cells induces suppression
of DNA synthesis, which in result activates correspond-
ing cell cycle checkpoints, and induces decrease of the
expression of Cyclin A, Cyclin B1 and Cdc2. All these
changes lead to a distinct down regulation of the com-
position of Cdk2-Cyclin A, Cdc2-Cyclin A and Cdc2-
Cyclin B1 complexes, which may active the intra-S
phase checkpoint and in result cause cells to arrest at S-
Figure 2 ORAOV1 silencing induces S-phase cell cycle arrest in HeLa cells. (A) Quantification of cell cycle distribution determined by flow
cytometry analysis at 48 hours posterior to the treatment. Data were Mean ± SE for triplicate experiments. (B) BrdU incorporation assay was
performed at 48 hrs posterior to the treatment. Each column represents a mean value of triplicate experiments in each group. Data are Mean ±
SE, *, P < 0.05. (C) Western blot analyses of the expression of Cyclin A, Cyclin B1, Cyclin E, Cyclin D1, Cdc2, and Cdk2. G3PDH was used as an
internal control for equal loading. Data were representative blots from three independent experiments.
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ORAOV1 in OSCC, ORAOV1 was found to induce S-
phase arrest in OSCC cells [4]. In the present study, we
want to determine if ORAOV1 is also involved in the
regulation of cell cycle progression in cervical cancer
cells. Our data clearly showed that S phase cell cycle
arrest occurred in ORAOV1-silenced HeLa cells with a
suppression of DNA synthesis and a decrease in the
expression of several cell cycle regulators such as Cyclin
A, Cyclin B1 and Cdc2.
Apoptosis is a complex, multistage, and many genes
involved process. Now, it has been understood to be
triggered by two distinct signaling pathways [24-27].
One is the death receptor pathway, regarded as the
extrinsic pathway; and the other is the mitochondrial
pathway, regarded as the intrinsic pathway. For extrinsic
pathway, the apoptotic cell death can be triggered from
the outside of cells by activating death receptors. Then,
through their ligands, such as TNF-a and Fas L, the
initiator Caspase 8 and 10 are cleaved and activated,
which lead to the motivation of their downstream effec-
tor Caspases, such as Caspase 3, 6, and 7 to kill the cell.
For intrinsic pathway, apoptosis is mediated by the
release of cytochrome c from the mitochondria, which
promotes the activation of procaspase-9 into its acti-
vated form Caspase 9, and activates the downstream
effector Caspase 3, 6, and 7 to trigger cell death. In the
intrinsic apoptotic pathway, P53 is proved to promote
cell apoptosis through promoting cytochrome c release;
while Bcl-2, a member of the Bcl-2 family proteins, has
an anti-apoptotic effect by prevent the release of cyto-
chrome c from the mitochondria. In the present study,
Figure 3 ORAOV1 silencing induces apoptosis in HeLa cells. (A) Analysis of HeLa cell apoptosis (sub-G1 cells) upon ORAOV1 silencing by
flow cytometry assay using PI staining. (B) Quantitative analysis of cell apoptosis by Annexin V and PI double staining. Data were Mean ± SE for
triplicate experiments, *, P < 0.05. (C) The effect of ORAOV1 silencing on the expression of P53, Bcl-2, Caspase-3, 8 and 9, and cytochrome c
(mitochondrial and cytosolic). G3PDH was used as an internal control for protein equal loading, and VDAC and b-actin was used as equal
mitochondria and cytosol loading control respectively. Data was representative blots of three independent experiments.
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cervical cancer HeLa cells. Further functional studies
showed that ORAOV1 silencing in HeLa cells could
increase P53 expression and decrease the Bcl-2 protein
level. Furthermore, the expression level of cytochrome c
in cytosol was found to be increased with its decrease in
the mitochondria, which means the releasing of cyto-
chrome c from the mitochondria. Then, with the activa-
tion of the downstream effectors, Caspase 9 and 3,
intrinsic apoptotic pathway is determined to be activated
by ORAOV1 silencing in HeLa cells. Besides the activa-
tion of intrinsic pathway, ORAOV1 silencing was also
found to active apoptosis through the extrinsic pathway
by inducing Caspase 8 and 3 cleavage and activation.
Therefore, ORAOV1 silencing was found to trigger
apoptosis in HeLa cells through both pathways, and
ORAOV1 is regarded to take a crucial part in the regu-
lation of HeLa cell growth through its roles in cell apop-
tosis regulation.
Cyclin D1 is an important protooncogene. Together
with its corresponding binding partner cyclin-dependent
kinases, CDK4 and CKD6, Cyclin D1 acts as a crucial
cell cycle regulator which has been regarded to take an
important part in the development and progression of
several cancers [28]. According to clinical sample stu-
dies, Cyclin D1 overexpression has been found in a vari-
ety of carcinomas, and have been linked to the early
onset, progression and metastasis of tumors [29]. For
cervical cancers, the prognostic value of Cyclin D1 was
supported by the tight correlation between its overex-
pression and the clinical grade of cervical cancer
[30,31]. In the present study, we found another impor-
tant gene for cervical cancer tumorigenesis, ORAOV1.
Interestingly, according to the mapping results of chro-
mosome 11q13, the distance between CCND1 and
ORAOV1 was less than 12 kb [1]. Given the functional
roles of Cyclin D1 and ORAOV1 in cervical cancer
tumorigenesis, the close proximity of these two genes
on chromosome 11q13, it is interesting to determine
whether there are interactions exist between these two
genes. According to our study, ORAOV1 specifically
knocked down by RNAi obviously suppressed the
expression of Cyclin D1, which suggests that Cyclin D1
may be a downstream effector of ORAOV1, and
ORAOV1 probably takes a part in the regulation of cell
growth in cervical cancer cells, in some degree, through
its effect on Cyclin D1.
In the present study, ORAOV1 silencing is determined
to inhibit HeLa cell growth in vitro. Thus, it is of great
interest to investigate whether it has similar effect in
vivo. Through tumor formation assay, ORAOV1 knock-
down is demonstrated to suppress the growth of HeLa
xenografts. Moreover, by HE staining, necrosis was
found in ORAOV1-silenced HeLa xenografts. Since
ORAOV1 silencing is found to induce cell cycle arrest
and cell apoptosis in HeLa cells, it can be deduced that
the necrosis in HeLa cell xenografts may be a result of
cell apoptosis induced by ORAOV1 knockdown.
Figure 4 ORAOV1 silencing suppresses the growth of HeLa cell xenografts in vivo. (A) The tumor volume curves. Data were the Means ±
SE (n = 5 tumors), *, P < 0.05; **, P < 0.01. (B) The final tumor weight at necropsy 25 days after seeding. Data were the Means ± SE (n = 5
tumors), *, P < 0.05. (C) ORAOV1 silencing induces necrosis in HeLa xenograft tumor tissues. (a) The representative HeLa cell xenografts of each
group. (b) Paraffin-embedded sections of representative HeLa xenografts were analyzed by HE staining. Arrows indicate necrosis in tumor tissues.
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SCCs of different origins, its functional roles in tumori-
genesis have been determined in these SCCs [1-4], it is
reasonable to speculate that ORAOV1 may be a com-
mon regulator in the tumorigenesis of SCCs, and a gen-
eral therapeutic target for the treatments. Moreover,
since two different splice variants of ORAOV1 have
been identified [32], the functions of ORAOV1 proteins
in SCCs seem to be complicated. Still, a large amount of
further studies are needed to clarify the biological func-
tions of ORAOV1 protein family in SCCs, as the biolo-
gical functions of each ORAOV1 splice variant remains
unclear.
Conclusion
In conclusion, we provide the first evidence that
ORAOV1 participates in the regulation of cervical can-
cer HeLa cell growth through its effect on the cell cycle
and apoptosis. Thus, it may be a valuable protooncogene
and therapeutic target for cervical cancer management.
Moreover, since its functional roles have been deter-
mined in tumorigenesis of various SCCs, ORAOV1 is
speculated to be a common regulator in SCCs tumori-
genesis, and a general therapeutic target for their
treatments.
Materials and methods
Preparation of siRNA and transfection
ORAOV1 siRNA (ON-TARGET plus SMARTpool,
Thermo Scientific Dharmacon) directed against
ORAOV1 (GenBank accession no. NM_153451) was
used to silence ORAOV1 in the present study. Non-Tar-
geting siRNA (ON-TARGET plus Control siRNA,
Thermo Scientific Dharmacon) was used as the negative
control. For siRNA transfection, transfection agent
DharmaFECT 1 (Thermo Scientific Dharmacon) was
used and the transfection was performed following the
manufacturer’s protocol.
Cell culture
HeLa cells were obtained from the State Key Laboratory
of Biotherapy and Cancer Center at Sichuan University
with its identity verified by the short tandem repeat
(STR) analysis (see additional file 1). In our study, HeLa
cells were cultured in DMEM (Gibco RL, Grand Island,
NY) with 10% fetal bovine serum (FBS; Gibco), 100
units/ml penicillin and 100 μg/ml streptomycin, and
incubated in a humidified 37°C incubator with 5% CO2.
Real-time RT-PCR analysis
Total RNA of each sample was isolated from cells by
RNeasy mini kit (Qiagen). The mRNA expression level
of ORAOV1 was detected using a quantitative 2-step
RT-PCR assay with ORAOV1 gene specific primers (for-
ward primer: CCCGCGUGCCGUUCUUACC; reverse
primer: CCGGCAGCUUCAGGCACAAAUG). The RT
was performed using Thermoscript RT-PCR system
(Invitrigen), and the real time PCR was performed using
SYBR Green PCR Master Mix (Applied Biosystems)
with the ABI 7900HT Sequence Detection Systems. The
relative mRNA expression level was determined using
the 2-delta delta Ct analysis method, where actin was
used as an internal reference.
MTT assay and plate colony assay
For MTT assay, HeLa cells were plated in 96-well plates
at a density of 1 × 10
4 cells per well. After transfection
for 96 hours, 10 μl MTT with 5 mg/ml concentration
was added to each well and cultured at 37°C for 4
hours. Then, the medium was discarded and 100 μl
DMSO was added to each well. After incubating for 10
minutes, the absorbance of each well was read by a
microplate reader (Model 550, Bio-Rad, Richmond, CA).
For plate colony assay, at 24 hours post-treatment, 3 ×
10
2 HeLa cells of each group were reseeded in each 60
mm tissue culture disk (Falcon) containing DMEM with
10% FBS, respectively, and cultured at 37°C for 2 weeks.
The cells were then stained with Giemsa and colonies
containing more than 100 cells were counted.
Cell cycle analysis
48 hours after the treatment, 2 × 10
6 HeLa cells of each
group were harvested by trypsinization, washed twice
with PBS, and fixed with cold 70% ethanol at 4°C over-
night. The cells were then washed once with PBS,
digested by 200 μl RNase (1 mg/ml) at 37°C for 30 min-
utes, and stained with 800 μl propidium iodide (50 μg/
ml) at room temperature for 30 minutes. Cell cycle ana-
lysis was done by using EPICS Elite ESP flow cytometrer
(USA).
Apoptosis assay
Apoptotic cell death was assessed by flow cytometry
assay using propidium iodide (PI) staining and Annexin-
V fluorescein isothiocyanate (FITC) and PI double stain-
ing. The flow cytometry assay using PI staining was per-
formed as described in the part of cell cycle analysis.
Annexin-V & PI double staining was performed using
Annexin-V FITC Apoptosis Detection Kit (R&D sys-
tems, Abingdon, UK) following the manufacturer’sp r o -
tocol. In brief, at 36 hours after the treatment, 2 × 10
5
trypsinized cells of each group were stained and ana-
lyzed by a flow cytometrer (BD FACSAria™).
Bromodeoxyuridine (BrdU) incorporation assay
BrdU incorporation assay was performed as described
elsewhere [33]. In brief, 48 hrs post treatments; cells
were labeled with BrdU (BD Pharmigen) for 1 hour and
fixed with 70% ethanol. Then, cells were stained with
anti-BrdU antibody and incubated with fluorescein iso-
thiocyanate (FITC)-conjugated secondary antibody. The
incorporation of BrdU was measured by fluorescence-
activated cell sorting (FACS) analysis with 10,000 cells
collected for each assay.
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Proteins in each group were isolated and subjected to
Western blot analysis as described elsewhere [34]. Isola-
tion of mitochondrial and cytosolic proteins was per-
formed using Mitochondria/cytosol Fractionation Kit
(Beyotime Inst. Biotech, Peking, PR China) following the
manufacturer’s protocol. Antibody to ORAOV1 was
from Abcam (AbCam, Cambridge, United Kingdom);
antibodies to P53, Caspase-3, Cyclin A, Cyclin D1,
Cyclin E, and Cdc2 were obtained from Cell Signaling
Technology (Beverly, MA); antibodies to Caspase-9, Bcl-
2, and G3PDH were from R&D systems (Abingdon,
UK); antibody to Caspase-8 was from Millipore; antibo-
dies to Cdk2, VDAC and b-actin was from Santa Cruz
Biotechnology (Santa Cruz, CA), and antibody to cyto-
chrome c was from PharMingen. The secondary antibo-
dies were HRP-linked anti-mouse (7076) or anti-rabbit
(7074) IgG from Cell Signaling Technology (Beverly,
MA), and anti-goat IgG antibody from Abcam
(ab30816). SuperSignal
@ West Pico (Pierce) was used to
detect the blots.
In vivo tumor formation assay
All animal studies were conducted following the U.S.
Public Health Service’s policy on humane care and use
of laboratory animals. Fifteen 6-week-old female BALB/
c-nu/nu nude mice were purchased from the Animal
Center of Sichuan University and randomly divided into
three groups of 5 mice each. 1 × 10
6 log-growing HeLa
cells transfected with ORAOV1 siRNA, negative siRNA,
or left untreated were harvested by trypsinization 12
hours after the treatment, washed twice with 1 × PBS,
suspended in 100 μl of DMEM without FBS and antibio-
tics, and injected subcutaneously into the right flank site
of each mouse. In the meantime, silencing of ORAO-
V1in these cells was confirmed by real-time PCR. All
the mice were kept in pathogen-free environments, and
the xenografts were measured by caliper every 5 days
for 1 month. In this study, tumor volume was calculated
by the following formula: tumor volume = 1/2 × (longer
diameter) × (shorter diameter)
2. All the mice were sacri-
ficed after 25 days.
Hematoxylin-eosin staining
The specimens of HeLa xenografts were fixed in 10%
buffered formalin, processed, and embedded in paraffin.
S e c t i o n sw e r ec u ta t3μm thickness and stained with
hematoxylin and eosin. The slides were examined with
Imager.Z1 microscope (Carl Zeiss), and all the micro-
graphs were taken with an AxioCam MRc5 camera
(Carl Zeiss).
Statistical analysis
Statistical analysis was performed with a single-tailed
unpaired Student’s t-test. Differences with P < 0.05 were
considered statistically significant.
Additional file 1: STR profiles of HeLa cells. The STR profiles of HeLa
cells analyzed by STR profile multiplex system PowerPlex® 16 kit
(Promega).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-20-
S1.TIFF]
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